RAYMOND JAMES & ASSOCIATES - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$28,047
-16.3%
23,7690.0%0.00%
Q2 2023$33,514
+5.5%
23,769
+12.3%
0.00%
Q1 2023$31,760
+34.6%
21,173
+5.0%
0.00%
Q4 2022$23,602
-1.7%
20,173
-4.5%
0.00%
Q3 2022$24,000
-22.6%
21,115
+7.7%
0.00%
Q2 2022$31,000
+3.3%
19,6130.0%0.00%
Q1 2022$30,000
-26.8%
19,613
+16.7%
0.00%
Q4 2021$41,000
-2.4%
16,8130.0%0.00%
Q3 2021$42,000
-12.5%
16,8130.0%0.00%
Q2 2021$48,000
+20.0%
16,813
-0.3%
0.00%
Q1 2021$40,000
+14.3%
16,857
-15.2%
0.00%
Q4 2020$35,000
+218.2%
19,878
+76.3%
0.00%
Q3 2020$11,000
+10.0%
11,2780.0%0.00%
Q2 2020$10,000
+11.1%
11,2780.0%0.00%
Q1 2020$9,000
-18.2%
11,278
-8.1%
0.00%
Q4 2019$11,000
-8.3%
12,278
+0.5%
0.00%
Q3 2019$12,00012,2130.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Defender Capital, LLC. 5,036,720$14,354,0004.77%
BROADWOOD CAPITAL INC 34,005,379$96,915,0004.33%
Prescott General Partners LLC 1,851,851$5,278,0000.17%
Raffles Associates 43,590$124,0000.10%
Laidlaw Wealth Management LLC 123,730$353,0000.09%
DCF Advisers, LLC 74,500$212,0000.08%
Beirne Wealth Consulting Services, LLC 45,000$128,0000.07%
Strategic Wealth Investment Group, LLC 64,232$183,0000.06%
Paradigm, Strategies in Wealth Management, LLC 19,775$56,0000.05%
Fort Sheridan Advisors LLC 47,931$137,0000.05%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders